Genomic profiling of malignant pleural mesothelioma with array‐based comparative genomic hybridization shows frequent non‐random chromosomal alteration regions including JUN amplification on 1p32

Genome‐wide array‐based comparative genomic hybridization analysis of malignant pleural mesotheliomas (MPM) was carried out to identify regions that display DNA copy number alterations. Seventeen primary tumors and nine cell lines derived from 22 individuals were studied, some of them originating from the same patients. Regions of genomic aberrations observed in >20% of individuals were 1q, 5p, 7p, 8q24 and 20p with gains, and 1p36.33, 1p36.1, 1p21.3, 3p21.3, 4q22, 4q34‐qter, 6q25, 9p21.3, 10p, 13q33.2, 14q32.13, 18q and 22q with losses. Two regions at 1p32.1 and 11q22 showed a high copy gain. The 1p32.1 region contained a protooncogene, JUN, and we further demonstrated overexpression of JUN with real‐time polymerase chain reaction analysis. As MPM cell lines did not overexpress JUN, our findings suggested that induction of JUN expression was involved in the development of MPM cells in vivo, which also might result in gene amplification in a subset of MPM. Meanwhile, the most frequent alteration was the 9p21.3 deletion, which includes the p16INK4a/p14ARF locus. With polymerase chain reaction analysis, we determined the extent of the homozygous deletion regions of the p16INK4a/p14ARF locus in MPM cell lines, which indicated that the deletion regions varied among cell lines. Our results with array comparative genomic hybridization analysis provide new insights into the genetic background of MPM, and also give some clues to develop a new molecular target therapy for MPM. (Cancer Sci 2007; 98: 438–446)

[1]  M. Kondo,et al.  Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients , 2006, Cancer science.

[2]  Daniel W Lin,et al.  Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Naoe,et al.  Genomewide array‐based comparative genomic hybridization analysis of acute promyelocytic leukemia , 2006, Genes, chromosomes & cancer.

[4]  M. Carbone,et al.  The pathogenesis of mesothelioma. , 2006, Seminars in diagnostic pathology.

[5]  S. Knuutila,et al.  Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases , 2006, Virchows Archiv.

[6]  B. Robinson,et al.  Advances in malignant mesothelioma. , 2005, The New England journal of medicine.

[7]  G. Giaccone,et al.  Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  T. Papp,et al.  Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. , 2005, Oncology reports.

[9]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[10]  T. Efferth,et al.  Homozygous deletions of CDKN2A caused by alternative mechanisms in various human cancer cell lines , 2005, Genes, chromosomes & cancer.

[11]  M. Jaurand,et al.  Pathogenesis of malignant pleural mesothelioma , 2005, Respirology.

[12]  H. Tagawa,et al.  Genome-Wide Array-Based Comparative Genomic Hybridization of Diffuse Large B-Cell Lymphoma , 2004, Cancer Research.

[13]  Hiroyuki Tagawa,et al.  Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. , 2004, Cancer research.

[14]  J. Minna,et al.  β-catenin inhibits cell growth of a malignant mesothelioma cell line, NCI-H28, with a 3p21.3 homozygous deletion , 2003, Oncogene.

[15]  Claude Denham,et al.  Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jun Yokota,et al.  Molecular processes of chromosome 9p21 deletions in human cancers , 2003, Oncogene.

[17]  W. Schulz,et al.  Peculiar structure and location of 9p21 homozygous deletion breakpoints in human cancer cells , 2003, Genes, chromosomes & cancer.

[18]  T. Omasa Gene amplification and its application in cell and tissue engineering. , 2002, Journal of bioscience and bioengineering.

[19]  K. Müller,et al.  Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases , 2002, The Journal of pathology.

[20]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[21]  J. Minna,et al.  Genetic alteration of the β-catenin gene (CTNNB1) in human lung cancer and malignant mesothelioma and identification of a new 3p21.3 homozygous deletion , 2001, Oncogene.

[22]  D. Weiss,et al.  Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. , 2001, International journal of oncology.

[23]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[24]  J. Testa,et al.  Recent advances in the molecular analysis of human malignant mesothelioma. , 2000, La Clinica terapeutica.

[25]  W. Dehnen,et al.  mRNA expression patterns in different stages of asbestos-induced carcinogenesis in rats. , 2000, Carcinogenesis.

[26]  J. Kere,et al.  Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis , 1999, British Journal of Cancer.

[27]  J. Testa,et al.  Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma , 1999, Journal of cellular physiology.

[28]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[29]  S. Jhanwar,et al.  Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. , 1999, Cancer research.

[30]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[31]  S. Jhanwar,et al.  Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. , 1997, Cancer research.

[32]  S. Jhanwar,et al.  Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. , 1996, Cancer research.

[33]  K. Pelin,et al.  Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. , 1996, Cancer genetics and cytogenetics.

[34]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[35]  J. Fletcher,et al.  Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.

[36]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[37]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[38]  S. Jhanwar,et al.  Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. , 1993, Cancer research.

[39]  N. Heintz,et al.  Persistent induction of c-fos and c-jun expression by asbestos. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[40]  B. Lanphear,et al.  Latent period for malignant mesothelioma of occupational origin. , 1992, Journal of occupational medicine. : official publication of the Industrial Medical Association.

[41]  R. Metcalf,et al.  p53 and Kirsten-ras mutations in human mesothelioma cell lines. , 1992, Cancer research.

[42]  M. Karin,et al.  The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. , 1991, Biochimica et biophysica acta.

[43]  T. H. van der Kwast,et al.  Cytogenetic analysis of malignant mesothelioma. , 1990, Cancer genetics and cytogenetics.

[44]  J. Testa,et al.  Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes , 1989, Genes, chromosomes & cancer.

[45]  S. Knuutila,et al.  Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. , 1988, Cancer genetics and cytogenetics.

[46]  R. Stahel,et al.  Chromosome changes in malignant mesothelioma. , 1986, Cancer genetics and cytogenetics.

[47]  D. Whitaker,et al.  The mesothelium and its reactions: a review. , 1982, Critical reviews in toxicology.

[48]  Ken Takahashi,et al.  Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model. , 2006, American journal of industrial medicine.

[49]  D. Fennell,et al.  Expression and prognostic significance of hypoxia-inducible factor 1α (HIF-1α) in malignant pleural mesothelioma (MPM) , 2006 .

[50]  J. Minna,et al.  Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  S. Knuutila,et al.  Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. , 1998, British Journal of Cancer.

[52]  G. Giaccone,et al.  Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  S. Knuutila,et al.  Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. , 1997, British Journal of Cancer.

[54]  J. DiPaolo,et al.  Nonrandom chromosome alterations in human malignant mesothelioma. , 1988, Cancer research.

[55]  Ramon Silva Martins,et al.  Malignant pleural mesothelioma. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.